Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Wom...(women's empowerment. Yet too often an ob...),Health

Date:6/6/2008

women's empowerment. Yet, too often, an obstacle prevents millions of women from living healthy, productive lives: cancer. Cervical cancer kills more than a quarter million women each year, and nearly all of these deaths are preventable. New vaccines and a highly accurate test for HPV have the power to eliminate this devastating disease. But we need help in assuring access to these medical advances for all women, and we welcome QIAGEN's commitment and leadership."

In addition to its digene HPV Test, which QIAGEN distributes widely in the United States, Europe and elsewhere, the company is partnering with the non-profit organization PATH to develop a specially designed version of the screening test for low-resource countries. This new test is sensitive enough to identify the largest number of women at risk - a critical characteristic when a woman may be able to get to a medical clinic just once or twice in her lifetime. Yet at the same time, the new HPV test can be run without electricity or running water, and can be administered by workers with minimal training.

"Public-private partnerships are essential to advancing the health agenda for women, and QIAGEN is committed to leading the way," Mr. Schatz told the audience at a panel discussion on corporate social responsibility at the summit. "We look forward to working in tandem with the many partners we have found at this summit and elsewhere."

About HPV and cervical cancer (http://www.theHPVtest.com)

Worldwide, cervical cancer affects nearly 500,000 women annually and, after breast cancer, is the second most common malignancy found in women. Cervical cancer is caused by "high-risk" types of the human papillomavirus (HPV), which are sexually transmitted. It's estimated that 80 percent of women will get an HPV infection at some point in their lives. However, in most cases, the infection goes away or is suppressed by the body without causi
'/>"/>

SOURCE QIAGEN NV Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
3. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
4. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
5. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
6. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
7. New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
8. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
9. GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years
10. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
11. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial